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Saline lavage with substitution of bovine surfactant in term
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Background:  Meconium aspiration syndrome (MAS) is still a condition
associated with a high mortality, and many patients require extracorporeal
membrane oxygenation (ECMO) as rescue therapy. Beneficial effects of
surfactant and perflubron lavage have been reported. However, pure surfactant
supplementation has not been proven to be beneficial in the most severe forms
of MAS. This study was performed to demonstrate an improvement in
oxygenation in neonates transferred for ECMO and fulfilling ECMO criteria with a
saline lavage and surfactant resupplementation.
Methods: Twelve newborns with MAS [gestational age 36–40 weeks, mean
birth weight 3200g, age 4–16h, oxygenation index (OI) >40] transferred for
ECMO therapy were treated with saline lavage (5–10cm3/kg body weight, as
long as green colored retrieval was observed) and resupplementation with
bovine surfactant (Alveofact, Boehringer, Ingelheim, Germany). The OI at
admission and 3h after this procedure was compared using the t-test for paired
samples. ECMO was available as rescue therapy at all times.
Results: The OI decreased from 49.4 (SD±13.3) to 27.4 (SD±7.3), P<0.01.
The decrease was sustained in nine patients, three patients required ECMO and
all patients survived.
Conclusions: As MAS is a condition with parenchymal damage, pulmonary
hypertension and obstructive airway disease, no simple causative therapy is
possible. Surfactant application after removal of meconium by extensive lavage is
feasible as long as 16h after birth even in infants considered for ECMO therapy;
it might reduce the necessity of ECMO.
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Introduction
Meconium aspiration syndrome (MAS) is a leading cause
of severe respiratory failure in term neonates and is associ-
ated with high mortality. Extracorporeal membrane oxy-
genation (ECMO) has improved the outcome of infants
with MAS significantly [1]. In addition, the enforcement
of standardized management algorithms, with detailed
advice for pharyngeal and in some cases tracheal suction-
ing, have reduced the incidence of MAS, especially in
Europe [2–7].
In our state, only four cases in 29000 deliveries were reg-
istered in 1997 [8]. In cases of MAS with moderate sever-
ity, exogenous surfactant therapy improves oxygenation
and increases the rate of survival [9].
Infants are still transferred, however, to ECMO centers
after prolonged periods of hypoxemia; in extreme condi-
tions, with oxygenation indices >40, the transport-associ-
ated mortality is high [10]. Treatment options that
improve the conditions in severe MAS and can be used in
all NICU are therefore warranted.
As MAS is a condition combining pulmonary hypertension
and obstructive airway disease with a considerable inflam-
matory reaction, a simple causative therapy is not possible
[2]. Exogenous surfactant has been proven to improve
oxygenation in animal models of MAS [11,12].
Clinical observations in severe cases of MAS, however,
are contradictory; in general, a marginal improvement in
oxygenation has been observed [13–17]. Lavage proce-
dures with either surfactant alone or fluorocarbons have
been published as case reports [18,19]. Two cases of
successful saline lavage followed by surfactant adminis-
tration have been reported [20]. We studied this methodin a pilot series of 12 patients consecutively admitted
with an oxygenation index (OI) >40. As the calculated
mortality in these infants is still 61% without ECMO
[1], our institutional review board (IRB) did not allow a
clinically controlled study comparing saline lavage fol-
lowed by surfactant with saline lavage alone or saline
lavage plus placebo (placebo material with a high viscos-
ity as surfactant). In addition, the IRB demanded that
ECMO had to be available at all times after admission of
these patients.
Patients and methods
All neonates admitted to our unit in their first 24h of life
with a diagnosis of MAS for evaluation of ECMO therapy
were considered suitable for this pilot study if their OI
(mean airway pressure×FiO2×100/paO2) was >40 at
admission. Exclusion criteria were the same as the usual
ECMO exclusion criteria, in other words a major congen-
ital malformation such as obvious chromosomal disorders,
congenital heart disease (excluded by echocardiography),
intracerebral hemorrhage (excluded by cerebral ultra-
sound) or no informed consent obtainable. All patients
were ventilated with the Babylog 8000 (Dräger, Lübeck,
Germany), the mean airway pressure was calculated by
the ventilator integrated software and arterial blood gases
were obtained at admission. Patients were recruited over
an 18-month period. The diagnosis of MAS was based on
patient’s history, typical chest X-rays, and the green
colored appearance of tracheal secretions. ECMO was
available at all times as a rescue therapy. Informed
consent of the custodians was obtained, and the IRB did
not have any objections against this study.
Under hand bagged ventilation a bronchoalveolar lavage
was performed with 5–10cm3 saline/kg in portions of
3cm3/kg as long as green colored retrieval was observed
(mean 7.7, SD±1.6). This procedure had to be performed
in a maximum of 3min; 100mg/kg bovine surfactant
(Alveofact, Thomae, Biberach, Germany) was applied via
a 5G feeding tube fed through a bronchoscopy adapter to
the bifurcation under continuous hand bagging over a
period of 2–3min. During the procedure, the patients
were monitored by electrocardiogram, impedance respiro-
graphy, blood pressure registration via arterial lines (Sire-
cust 404N, Siemens, Erlangen, Germany) and pulse
oximetry (Dräger Oxisat 2, Dräger, Lübeck, Germany).
Arterial blood gases were again obtained 3h after the pro-
cedure. The oxygenation indices before and after the
lavage/surfactant resupplementation procedure were com-
pared using the t-test for paired samples. The primary
endpoint of this study was to observe a significant
decrease in the OI 3h after the lavage/surfactant resupple-
mentation procedure. P<0.05 was accepted as the level of
significance. We calculated a sample size of 10 to achieve
this level of significance with a b error of 5%, if the
decrease in OI was >20%.
The number of patients requiring ECMO in the further
course of their disease was documented. Venoarterial
ECMO was started if the OI was >40 for 8h or the paO2
<35 for 2h.
In all patients, a ventilatory strategy based on the concept
of low tidal volume ventilation was followed after the pro-
cedure. A lowest arterial pH of 7.2, paO2 of 45 and SaO2 of
85% were acceptable. For hemodynamic stabilization
dopamine, dobutamine, epinephrine, and norepinephrine
were used to keep the mean arterial blood pressure
>45mmHg, the heart rate between 140 and 200beats/min,
and maintain urinary output at 1cm3/kg perh.
All patients were followed in our neurodevelopmental
clinics over a 12-month period. Secondary endpoints were
taken as the survival rate compared with the UK-ECMO
trial [1], the rate of infants requiring ECMO, and the rate
of intact survival (no oxygen and no major neurological
handicaps at 1 year of age).
Results
We included 12 neonates with MAS transferred from
outside centers for evaluation of ECMO therapy in our
study (Table 1). The mean oxygenation index decreased
significantly from 49.4 (SD±13.3) before the lavage/surfac-
tant supplementation procedure to 27.4±7.3 after the pro-
cedure (P<0.01,  t-test for paired samples; Fig 1). The
oxygenation index 1h after the procedure was 38.6±8.9
and was not significantly different.
The improvement in oxygenation was sustained in nine
patients; in other words, no secondary increase of OI was
observed (OI in these patients 48 h after the procedure
19.2±3.1). All of these could be weaned off ventilation (time
on ventilator: 6–17 days) and were discharged home without
oxygen supplementation. The improvement in oxygenation
was reflected in the clearing of infiltrates on chest X-rays at
day 2 after the procedure (Figs 2 and 3). In three patients
the initial improvement of OI was not sustained; these were
treated with venoarterial ECMO, weaned successfully and
discharged home without oxygen supplementation. ECMO
was started in these three patients 7, 7.5, and 11h after the
lavage/surfactant procedure.
No late deaths were registered (observation time
12 months). The lavage/hand bagging/surfactant adminis-
tration procedure did not cause pneumothoraces or cardiac
arrests. Bradycardia (<80beats/min) lasting less than 30s
was observed in all patients.
In neurodevelopmental follow-up clinics, none of the 12
patients exhibited signs of severe neurological complica-
tions; the neurodevelopmental delay was 4 months at the
age of 12 months in one patient, the others had a normal
neurodevelopmental examination.
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MAS is the leading cause of respiratory failure in term
neonates and the major indication for ECMO therapy [1].
Prophylaxis by enforcement of standard suctioning proce-
dure (vigorous pharyngeal followed by tracheal suctioning
in infants with continued respiratory distress) in all obstet-
ric units has not been very successful [2]. ECMO is a very
successful therapy for MAS that was previously associated
with a high mortality [1]; however, many infants still
succumb before, during, and shortly after transport to
ECMO centers [10]. Surfactant to treat MAS should be
available in all level I and II neonatal facilities as it has
been shown to be successful in resuscitation after meco-
nium aspiration in two cases [20].
In animal models of MAS a beneficial effect of surfactant
therapy has been demonstrated [11,12,18,21,22]. This was
attributed to the anti-inflammatory, alveolar recruiting,
and pulmonary vasodilatative effect of surfactant [16,
21–25]. Clinical studies, however, lead to very contradic-
tory, predominantly discouraging results [13,14,16,21,24,
25]. This might be because of the fact that, until recently,
surfactant preparations had a high viscosity that made it
unsuitable for lavage and caused airway obstruction in
these patients with an already underlying obstructive
airway disease. Our group has observed these difficulties
in surfactant treatment studies in acute respiratory distress
syndrome (ARDS) in infants and children, where the
initial trials caused a sudden deterioration of the oxygena-
tion after surfactant bolus application [26]. A recent clini-
cal controlled study of surfactant therapy in term infants
including a considerable number of patients after meco-
nium aspiration could demonstrate a significant improve-
ment in oxygenation after surfactant use; however, these
infants with a mean OI of 25 were suffering only from
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Figure 1
Oxygenation index (mean airway pressure×FiO2×100/paO2) before
and after saline lavage and surfactant resupplementation in 12
neonates (mean 75th and 97th percentile).
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Figure 2
Chest X-ray in one patient at admission, demonstrating features of
meconium aspiration.
Figure 3
Chest X-ray 2h after lavage/surfactant procedure in the same patient
as in Fig 1, showing clearing of infiltrate.
Table 1
Characteristics of the 12 infants studied
Mean birth weight (± SD) 3200 g (± 444)
Mean gestational age (range) 38.8 weeks (36–42)
Mean 5-min APGAR (range) 6.4 (4–9)
Girls/boys 7/5
c-sections/vaginal deliveries 2/10
APGAR, American Pediatric Gross Assessment Record.moderate MAS [9]. This group of patients in our region
has a mortality of <15% and is therefore not comparable
with the patient group we studied [8,26]. Initial reports
using fluorocarbons for lavage and alveolar recruitment in
MAS patients have been published [19].
In our study, we followed a protocol based on quick saline
lavage followed by surfactant resupplementation to over-
come these difficulties. As a controlled study comparing
surfactant with a placebo of the same high viscosity
causing airway obstruction in this patient population with
a mortality >60% [1] was not acceptable for our IRB, we
tried to overcome a selection bias by including at least all
consecutively admitted neonates with MAS and an OI
>40 to our institution over a 2-year period. This pilot
study showed a marked improvement in oxygenation in
MAS patients. The need for ECMO was low; in the UK-
ECMO study all patients would have been suitable for
ECMO therapy. However, as the overall number of
patients evaluated was small, the power of this study to
prove a decrease in ECMO necessity was low (b error
10%). In addition, it has to be borne in mind that the con-
clusion of Wiswell et al [2] in 1990 that we had made no
difference in MAS might no longer be true. Standard
treatment protocols, nitric oxide, and occasional surfactant
application have lowered the number of patients requiring
ECMO recently [8,17].
We would conclude from our pilot study that saline lavage
followed by surfactant application in MAS patients is fea-
sible and improves oxygenation; it might lower the need
for ECMO or reduce the transport-related mortality in
neonates with MAS, which exceeds 25% in a study based
in Germany [28].
Its value in comparison with fluorocarbons and new recon-
stituted surfactant preparations with a lower viscosity has
to be studied in the future. The latter might be used as
lavage fluid alone and be beneficial as a simple therapeu-
tic agent comparable with the indication in term infants
with respiratory failure with a lower OI [9].
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